These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35733352)

  • 1. Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study.
    De Luca L; Calabrò P; Chirillo F; Rolfo C; Menozzi A; Capranzano P; Menichelli M; Nicolini E; Mauro C; Trani C; Versaci F; Tomai F; Musumeci G; Di Mario C; Pepe M; Berti S; Cernetti C; Cirillo P; Maffeo D; Talanas G; Ferlini M; Contarini M; Lanzilotti V; Scherillo M; Tarantini G; Muraglia S; Rossini R; Bolognese L;
    Clin Cardiol; 2022 Sep; 45(9):913-920. PubMed ID: 35733352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and safety of cangrelor in patients with suboptimal P2Y
    Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
    BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of cangrelor and transition to oral P2Y
    De Luca L; Calabrò P; Capranzano P; Di Mario C; Chirillo F; Rolfo C; Menozzi A; Menichelli M; Bolognese L; Musumeci G
    Eur Heart J Open; 2023 Jul; 3(4):oead076. PubMed ID: 37646045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Yerasi C; Case BC; Chezar-Azerrad C; Forrestal BJ; Medranda GA; Shea C; Zhang C; Ben-Dor I; Satler LF; Bernardo NL; Hashim H; Garcia-Garcia HM; Waksman R
    Am Heart J; 2021 Aug; 238():59-65. PubMed ID: 33961829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor.
    Benenati S; Gragnano F; Scalamera R; De Sio V; Capolongo A; Cesaro A; Annibali G; Campagnuolo S; Silverio A; Bellino M; Centore M; Schettino M; Bertero E; Caretta G; Rezzaghi M; Veneziano F; De Nardo D; De Rosa G; De Luca L; Galasso G; Menozzi A; Musumeci G; Cirillo P; Calabrò P; Porto I
    Int J Cardiol; 2024 Dec; 417():132568. PubMed ID: 39284439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome.
    Kubica J; Adamski P; Dobrzycki S; Gajda R; Gąsior M; Gierlotka M; Jaguszewski M; Legutko J; Lesiak M; Navarese EP; Niezgoda P; Ostrowska M; Pawłowski T; Tycińska A; Umińska JM; Witkowski A; Gil R
    Cardiol J; 2024; 31(1):133-146. PubMed ID: 37964649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the Role of Cangrelor in Patients Undergoing PCI?
    Droppa M; Geisler T
    Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
    Capodanno D; Milluzzo RP; Angiolillo DJ
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
    Mostafa MR; Eid MM; Awad AK; Takla A; Hassan AR; Katamesh BE; AlBarakat MM; Ziada AR; Mohamed S; Al-Azizi KM; Goldsweig AM
    Am J Cardiovasc Drugs; 2024 Jan; 24(1):71-81. PubMed ID: 37995040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
    Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
    Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study.
    Bruno F; Wenzl FA; De Filippo O; Kraler S; Giacobbe F; Roffi M; Muller O; Räber L; Templin C; De Ferrari GM; D'Ascenzo F; Lüscher TF;
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):391-402. PubMed ID: 38604747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.